Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Spine SurgeryReversal of Neuromuscular BlockadeUrinary Retention Postoperative
Interventions
DRUG

Sugammadex

Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.

DRUG

Neostigmine

Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.

DRUG

Glycopyrrolate

Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.

DRUG

Rocuronium

To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.

Trial Locations (1)

65212

University Hospital, Columbia

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Missouri-Columbia

OTHER